Background: Respiratory enteric orphan (reo)virus is a promising oncolytic viral candidate. Reoviral anticancer therapy is currently undergoing multiple clinical trials targeting various human cancers; however, there is no effective reoviral inhibitor that can be used to block unwanted
Respiratory enteric orphan (reo)virus is a ubiquitous, non-enveloped virus containing 10 segments of doublestranded RNA as its genome, causing human infections that are generally mild, restricted to the upper respiratory and gastrointestinal tracts and which are often asymptomatic [1] . Importantly, reovirus has been recognized for many years as displaying striking cytocidal activity when it infects certain types of transformed cells [2, 3] . The underlying basis for reoviral oncolytic activity remained unknown until it was shown that transformed cells containing oncogenic Ras signalling pathways were preferentially susceptible to reovirus infection (serotype 3 Dearing strain) in vitro and in vivo [4] [5] [6] . As Ras gene mutations are frequently observed in various types of human cancers [7] , these findings have led to the current use of reovirus in clinical trials [5, 8] ; however, in immunocompromised hosts, such as newborn and severe combined immunodeficiency (SCID) animals, the wild-type reovirus causes significant viral pathogenesis, especially in neural and cardiac muscle tissues [9] [10] [11] [12] . In some cases, even in immunecompetent hosts, including humans, the wild-type reovirus has been associated with viral pathogenesis [13, 14] ; therefore, especially in immunocompromised or very young hosts, the wild-type reovirus does not always act in a benign manner. We speculate that this concern might apply, in some cases, to cancer patients treated with extensive radio/chemotherapy, as they can 
Methods

Cell lines, viruses and Z-FA-FMK
Human fibrosarcoma cell line HT1080 and the ES-D3 mouse embryonic stem cell line were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA; CRL-11632) and the latter were maintained in their undifferentiated state with 1×10 6 U/ml of leukaemia inhibitory factor in media made according to ATCC protocols. ES-D3 cells were plated in six-well plates at 4.8×10 5 cells per well and grown at 37°C at 95% humidity and in 5% CO 2 . To establish persistently infected cells with reovirus, reovirus-susceptible HT1080 cells were infected with wild-type reovirus at a multiplicity of infection (MOI) of 20, then the few surviving cells were maintained until they reached confluency. The surviving cells were subsequently reinfected three times for 3-7 weeks to select virally resistant cells. Initially, these surviving cells grew slowly and sometimes underwent crisis, resulting in few surviving cells [15] , but eventually they became established cell lines. From the surviving HT1080 cells, several subclones were obtained by serial dilution. Clone HTR1 (HT1080 virally resistant clone 1) was used for this study. The HTR1 cells were persistently infected and maintained for >48 months [16] . The Dearing strain of reovirus serotype 3 used in these studies was propagated in suspension cultures of L929 cells (ATCC) and purified according to previously established methods [17] with the exception that b-mercaptoethanol was omitted from the extraction buffer. For reovirus titration, HEK 293 cells (ATCC) were plated in six-well plates at 2×10 5 cells per well. After 2 h of adsorption at 37°C, the inoculum was removed. Cell monolayers were then covered with 1% agar and fresh medium. Plaques were counted 5-7 days after infection. Mv1Lu cells were purchased from ATCC and maintained according to ATCC protocols. A New Caledonia/20/99-like virus (H1N1) was isolated from a respiratory specimen of a patient with acute influenza-like symptoms. The virus was isolated in primary rhesus monkey fibroblastic cells and subtyping was undertaken by H1 serotyping and nucleic acid sequencing at the Provincial Laboratory for Public Health (Microbiology Department, University of Calgary, Calgary, AB, Canada) and the National Microbiology Laboratory (Winnipeg, MB, Canada). Subtyping studies confirmed the virus is similar to that included in the current inactivated influenza virus vaccine. Ghost CXC chemokine receptor type-4 cells obtained from the National Institutes of Health AIDS Research and Reference Reagent Program (Bethesda, MD, USA) were maintained in a media containing high glucose Dulbecco's modified Eagle's medium (90%; Gibco-Invitrogen, Burlington, ON, Canada) and fetal bovine serum (10%) supplemented with G418 (500 µg/ml), hygromycin (100 µg/ml), puromycin (1 µg/ml) and penicillin/streptomycin. HIV type-1 (HIV-1) NL4-3 strain was propagated as described previously [18, 19] . Z-FA-FMK was purchased from Imgenex (San Diego, CA, USA).
Immunoblot, immunostaining and fluorescenceactivated cell sorting analyses
Cell lysates were prepared by sonication in a buffer containing 10 mM Tris (pH 7.4), 2 mM EDTA, 1% NP-40, 50 mM mercaptoethanol, 100 µg/ml leupeptin and 2 µg/ml aprotinin. The lysates were then cleared by centrifugation at 16,000 g for 15 min, normalized for protein amount, mixed with SDS sample buffer, boiled for 5 min and stored at -70°C. After separation by SDS-PAGE, proteins were transferred to nitrocellulose membranes and detected by immunoblot hybridization. The primary antibodies (Abs) were as follows: antireovirus polyclonal Ab [16] 
Electron microscopy
Electron microscopy (EM) preparation was performed by the University of Calgary Microscopy and Imaging Facility (Calgary, AB, Canada). Cells grown on glass slides were rinsed briefly with phosphate-buffered saline (PBS) and fixed with 4% EM grade glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 1 h at room temperature (RT). After washing three times with the same buffer, cells were post-fixed in 1% osmium tetroxide buffered with 0.1 M cacodylate for 1 h at RT. Then cells were rinsed twice briefly with distilled water and stained en bloc for 30 min in 0.5% aqueous uranyl acetate. The cells were then dehydrated in an ethanol series and embedded in Spurr's low viscosity resin. Thin sections were cut with a diamond knife on a Reichert Ultracut E (Reichert Analytical Instruments, Depew, NY, USA), stained with uranyl acetate and lead citrate and examined with a Hitachi H-7000 transmission electron microscope (Hitachi, Mississauga, ON, Canada) at 75 kV.
Animal studies SCID mice (6-8 weeks old; Charles River, Wilmington, MA, USA) received a single subcutaneous implantation of 5×10 6 HT1080 cells suspended in PBS. After palpable tumours were established (11 days after implantation), tumours were injected with live reovirus (five tumours), ultraviolet-inactivated reovirus (five tumours), Z-FA-FMK (five tumours) and live reovirus suspended in Z-FA-FMK solution (five tumours). Tumour growth was measured externally using calipers and the volume was determined by the equation V=(L×W 2 )×0.5, where L is the largest dimension and W is the largest dimension perpendicular to L. Z-FA-FMK was dissolved in dimethyl sulfoxide and administered as 0.02 mg suspended in PBS intratumourally per mouse everyday up to 7 days post-viral injection, and every 2 days until completion of the experiment. All the mice were treated according to protocols approved by the University of Calgary Animal Care Committee.
Immunohistochemistry
All specimens taken from animals were fixed in 10% buffered formalin solution at RT. For reovirus antigen detection (reovirus structural proteins), deparaffinized tumour sections were retrieved in a solution containing 50 mM Tris (pH 7.5), 120 mM NaCl, 0.2% Tween 20 and 0.1% Triton X-100. After blocking the sections with a solution containing 50 mM Tris (pH 7.5), 120 mM NaCl, 0.2% Tween 20, 0.1% Triton X-100 and 2% normal goat serum for 1 h, the sections were immunostained with a solution containing 0.1% reovirus antiserum, 50 mM Tris (pH 7.5), 120 mM NaCl, 0.2% Tween 20, 0.1% Triton X-100 and 2% normal goat serum for 2 h. As a secondary Ab, biotinylated goat antimouse Ab (Vector Laboratories, Burlingame, CA, USA) was used at 1:100 in a solution containing 50 mM Tris (pH 7.5), 120 mM NaCl, 0.2% Tween 20, 0.1% Triton X-100 and 2% normal goat serum for 2 h at RT. Detection was monitored by a diaminobenzidine tetrahydrochloride-based immunohistochemistry protocol (diaminobenzidine substrate kit) according to the suggestions of the manufacturer (Vector Laboratories). Tumour slides were stained with the nickel solution from the kit. Dehydration was carried out in a series of graded ethanol solutions, followed by clarification in xylene. Slides were mounted with Vectamount (Vector Laboratories) and stored at 25°C.
Results
Z-FA-FMK blocks reoviral replication and cures cells of a persistent infection with reovirus in vitro
Z-FA-FMK is a cell-permeable cathepsin B inhibitor [15, 20, 21] . Because suppression of cellular cathepsin B partially affects reovirus replication by inefficient proteolytic disassembly of viral outer-capsid proteins [22, 23] , we speculated that pharmacological inhibition of cellular cathepsin B activity by Z-FA-FMK might also affect reovirus replication. Thus, we treated a reovirussusceptible cancer cell line, HT1080 [16] and a mouse embryonic stem cell line with Z-FA-FMK. Unexpectedly, instead of a partial viral inhibition, Z-FA-FMK completely blocked reovirus replication ( Figure 1A , 1B and 1C). Furthermore, Z-FA-FMK treatment cured persistently infected cells with reovirus (HTR1; Figure  1D ). Antiviral activity of Z-FA-FMK was also evaluated by FACS analysis. As shown in Figure 1E , Z-FA-FMK effectively suppressed reoviral replication potential in a dose-dependent manner. Despite the profound inhibition of viral replication, we observed no decrease in cell viability or colony forming efficiency in the presence of Z-FA-FMK ( Figure 1F ), consistent with earlier reports of its tolerability in vitro and in a mouse model system in vivo [24] ; thus, Z-FA-FMK is a potent antireoviral inhibitor in vitro.
Z-FA-FMK induces defects in reoviral maturation
Although cellular cathepsin B activity plays a role in reoviral replication, it has been shown that cathepsin B inhibition alone is not sufficient to block reoviral replication [23] ; thus, we speculated that Z-FA-FMK could significantly affect other steps of the reoviral infection cycle, in addition to cathepsin B-mediated inhibition, in order to exert the potent antiviral activity as shown above. We analysed Z-FA-FMK-treated cells under EM in order to examine virion morphological changes after Z-FA-FMK treatment. As shown in Figure 2 , untreated cells developed normal appearing viral factories at 48 h post-infection; however, Z-FA-FMK-treated cells did not form these viral factories and scattered viral particles were detected with perinuclear localization. More interestingly, all of the scattered viral particles contained empty capsids ( Figure 2B ), in comparison with crystalline arrays of full or empty capsids, in a progressive manner seen in the untreated cells (Figure 2A ; see also [24, 25] ). Therefore, Z-FA-FMK appears to block a virion morphogenesis step resulting in inhibition of viral factory development. 
Z-FA-FMK does not affect replication of other viruses
Because the antiviral effects of Z-FA-FMK on reovirus are so potent, we wished to examine the possibility that Z-FA-FMK might also affect other viruses by inhibition of a virion maturation step and/or a cellular endocytic pathway; thus, we examined the effects of Z-FA-FMK on influenza A virus, which is known to use a cellular endocytic pathway during its infection cycle [26] , and on HIV-1 virus by FACS and immunostaining analysis. Z-FA-FMK did not affect the viral replication activity of either influenza A or HIV-1 ( Figure 2C and 2D) ; therefore, within this limited comparison, it appears that Z-FA-FMK specifically affects reovirus infection, and further, that it blocks a reovirus virion maturation step during the reovirus infection cycle in an endosomeindependent manner.
Z-FA-FMK blocks reovirus infection in vivo
Because inhibition of the reoviral replication by Z-FA-FMK is so effective in vitro, we further examined the possibility that Z-FA-FMK might also affect reoviral infection in vivo. To evaluate the in vivo antiviral activity of Z-FA-FMK, we used a tumour xenograft model using SCID mice because reovirus replicates well in Ras oncogenic tumours in vivo [4, 6, 16] . Because SCID mice are highly susceptible to reovirus-induced viral myocarditis [10] , the viral replication activity in both tumour and host heart can be monitored by this tumour xenograft model. Thus, Ras oncogenic HT1080 cells were xenografted in SCID mice and either reovirus alone or reovirus supplemented with Z-FA-FMK was administrated intratumourally. At 16 days post-viral injection, tumour and heart tissues were examined by immunohistochemical analysis. As shown in Figure 3 , reovirus-treated mice showed extensive viral replication at both tumour sites and in heart tissues. Viral replication in the tumours caused suppression of tumour growth and viral replication in the host heart tissues induced massive lymphocyte infiltration, which is a typical pathological manifestation of viral myocarditis ( Figure 3B) . However, reovirus replication activity in both tumour and heart tissues was effectively blocked by Z-FA-FMK treatment ( Figure 3B) ; therefore, Z-FA-FMK systemically and effectively inhibits reovirus infection in vivo. The Ghost CXCR4 cell line carried the HIV type-1 long terminal repeat-driven green fluorescence protein gene, which becomes activated upon infection with HIV type-1 and thus became fluorescent (bottom panels) [30] .
Discussion
We have identified a novel peptide inhibitor with specific antiviral activity against reovirus at low micromolar concentrations. Peptidyl fluoromethylketones with the amino acids phenylalanine and alanine in the P2 and P1 positions, respectively, were shown to be irreversible inhibitors of some members of the cathepsin enzyme family [20, 27] . In particular, Z-FA-FMK was found to be a potent inactivator of cellular cathepsin B and binds tightly to the active site of the enzyme. Once bound to the active site, the cysteine residue there is alkylated by the fluoromethylketone group, which irreversibly blocks its proteolytic activity. Cathepsin B is a cysteine protease found mainly in the lysosomes [28] . It has been previously shown that cathepsin B plays a role in the proteolytic disassembly of viral outer-capsid proteins leading to proteolytic activation of reovirus virion, and pharmacological inhibition (using CA-074Me) of cellular cathepsin B contributes to decreased viral yields (although not a complete blockage of viral replication [23] ). Therefore, it is probable that Z-FA-FMK-mediated complete blockage of the viral replication occurs, at least in part, via a different mechanism in addition to inhibition of the proteolytic disassembly of viral outer-capsid proteins. We note further that it is unlikely that differential activity of double-stranded RNA-dependent protein kinase can explain the effects we see here, especially as evidence has been accumulating that the serotype 3 (Dearing) strain of reovirus that we used is insensitive to RNAdependent protein kinase activity [29] . Mammalian orthoreoviruses are believed to replicate in distinctive, cytoplasmic inclusion bodies, commonly called viral factories, following virion entry, proteolytic activation and cytoplasmic transcription and translation. A great deal remains to be understood about the assembly of viral capsids, genomic assortments and virion packaging [30] . As shown in the EM analysis, our data suggest that there is a significant blockage of the reovirus virion packaging and subsequent viral factory development upon Z-FA-FMK treatment, resulting in an empty virus particle. Because proteolytic activation of the reovirus virion appears to yield reovirus particles for the next steps in infection, such as endosomal membrane interaction and penetration [30] , it is probable that Z-FA-FMK does not significantly affect the virion proteolytic activation step. This is because the defective virion particles are present in the perinuclear region and other endocytic dependent viruses, such as influenza A and adenovirus (MK and RNJ, data not shown), are not affected by Z-FA-FMK. Thus, it is possible that Z-FA-FMK specifically affects unknown viral/host factors involved in virion packaging and factory development during reovirus infection. Because the maturation processes, including packaging, of reovirus virion are unique, it is likely that Z-FA-FMK specifically affects a reovirus packaging step, although this inhibitor might also block replication of other members of the Tumours and heart tissues were taken from the mice at 27 days post-implantation (16 days post-viral infection). Paraffin sections of tumours and heart tissues were analysed by indirect immunohistochemical staining using reovirus antiserum as described in Methods. Deep purple staining of tumours represents positive reoviral protein and the sections were counterstained with haematoxylin. Brown staining of heart tissues represents positive reoviral protein and the sections were counterstained with methyl green.
Reoviridae and related viruses. It has been suggested that muNS, sigmaNS and sigma 3 play a role in the reovirus RNA packaging process [30] ; thus, it is possible that Z-FA-FMK might specifically affect the normal function of these packaging-related reoviral proteins. Although reovirus is generally benign in human infections, reovirus-induced pathogenesis might occur in immunocompromised animal hosts [10, 16] . Reovirus also adversely affects development of rat and murine embryos, retarding development and inhibiting blastocytst formation [31, 32] . Because of the effective reoviral inhibition of Z-FA-FMK, we suggest that this agent might be useful in the modulation of viral replication activity during reoviral anticancer therapy in humans or in other therapeutic applications of reovirus.
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